Ubiquitin-proteasome pathway and prostate cancer.

Abstract

Prostate cancer is one of the most common cancers in men. Various signaling pathways and proteins are involved in prostate carcinogenesis. Ubiquitination and deubiquitination of the related proteins contribute to the development of prostate cancer in various ways. The ubiquitin-proteasome (UPS) system is a common cellular process for protein degradation in eukaryotes. In this article we review recent advances related to the involvement of the UPS pathway in prostate cancer. The UPS pathway plays an important role in the regulation of cellular proteins with respect to cell cycle control, transcription, apoptosis, cell adhesion, angiogenesis, and tumor growth. It is involved in prostate cancer in various ways by modulating prostate cancer-related genes/proteins such as androgen receptor, cyclin-dependent kinase inhibitor P27, cyclin D1, and PTEN. Some ubiquitin-like modifier proteins have also been found to be associated with prostate cancer. The UPS pathway represents a potential therapeutic target for prostate cancer, and proteasome inhibitors represent a class of chemotherapeutic agents that inhibit tumor growth. The UPS pathway is related to prostate cancer in different ways. More research on that link is needed, as targeting the UPS pathway has led to some success in prostate cancer treatment.